Currently, combinations of anti-VEGF (Vascular Endothelial Growth Factor, VEGF) and immune checkpoint inhibitor treatments are under investigation, which if successful, will significantly alter the therapeutic landscape for RCC treatment (Motzer et al., 2015). Here, VEGFA is linked to renal cell carcinoma.